To overcome this metabolic competition and bolster CD8+ T cell immunity, several strategies have been explored: Depleting or inhibiting ACSS2 in cancer cells blocks acetate utilization, redirecting acetate to CD8+ T cells and enhancing their antitumor function 57. Here, CD8A is linked to cancer.